The private sector, short of funding, is finding NIH a useful source of support. As large-scale biomedical research becomes prevalent and as industry's early-stage R&D productivity falters, both parties have an interest in collaborating more than in the past. But in general, NIH isn't set up to manage the transformation of so many promising discoveries into clinically useful products. It's determined to change that situation with the introduction in October of this year of a "roadmap" for collaborations of many kinds.
Even before this event, however, NCI, the largest institute within NIH, had undertaken several public-private programs to expedite development of new products. The institute's experiences illustrate some of advantages and pitfalls of public-private initiatives.
By Wendy Diller
National Institutes of Health (NIH) Director Elias Zerhouni, MD's announcement in early October 2003 of a new "roadmap" for moving promising basic research discoveries into the clinic faster is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.
Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.
GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.
In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.
Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.
